RenDong Medicine Files IPO Prospectus Highlighting Asia's Largest Prostate and Urothelial Cancer Databases Built Over a Decade

The Practice and Application of Precision Medicine in Urology Are Pioneering a Reshaping of Disease Diagnosis and Treatment Paradigms. In the diagnosis and treatment of urological diseases, precision medicine provides patients with more accurate and efficient medical services by integrating advanced diagnostic technologies, multi-omics data, and personalized treatment plans. The practice and application of precision medicine in urology have become the core driving force propelling the field toward a new era of refined and personalized diagnosis and treatment, continuously optimizing the protocols for managing urological diseases.

As a leading enterprise in the precision diagnosis and treatment of urological diseases, Gloriousmed adheres to its core competency by focusing on what it does best. Leveraging its proprietary multi-omics testing platform and multidimensional integrated analysis platform, the company provides precise and efficient diagnostic and therapeutic services to patients with urological conditions.At the 2025 VBEF Top 100 Future Healthcare and Pharmaceuticals Expo · Forum on the Development of Precision Medicine and Molecular Diagnostics Industry, Jin Ge, CEO of Gloriousmed, delivered a keynote address titled “Practice of Precision Medicine in Urology,” discussing technological advancements and application prospects in this cutting-edge field.

Jin Ge, CEO of Gloriousmed

The core of precision medicine lies in the precise diagnosis of diseases, and the integration and analysis of multi-omics data are key to achieving this. Jin Ge pointed out, “Through years of practice, Gloriousmed has accumulated a vast amount of omics data, including genomics, transcriptomics, proteomics, and metabolomics. These data provide a solid foundation for the precise diagnosis of urological diseases.”

For example, in the diagnosis of prostate cancer, Gloriousmed identified CDK12, a high-frequency mutation specific to Asian prostate cancer patients, through genomic studies of Asian populations. The company also validated its concordance between late-stage prostate cancer tissue and blood samples (91.7%). This discovery not only provides a new biomarker for the precise diagnosis of prostate cancer but also offers a critical basis for subsequent personalized treatment strategies.More importantly, leveraging data accumulated over the past decade, Gloriousmed has established Asia’s largest databases for prostate cancer and urothelial carcinoma, laying a solid foundation for subsequent precision medicine R&D.

In the specialized field of urology, Gloriousmed’s competitive edge is further demonstrated by its status as a research-driven enterprise advancing toward integrated diagnosis and treatment. By integrating diagnostic, therapeutic, and management services, the company not only enhances the efficiency and quality of healthcare delivery but also provides patients with a more convenient medical experience. To achieve this goal, Gloriousmed has established a complete industry chain comprising a research institute, a clinical laboratory, an in vitro diagnostic (IVD) kit manufacturing company, and a medical device sales company. Through the synergistic development of this industry chain, Gloriousmed is able to offer one-stop medical services to patients with urological diseases.

Will this integrated, full-industry-chain layout for diagnosis and treatment create competitive relationships with partners across the industry chain, such as diagnostic companies, medical device manufacturers, and pharmaceutical firms? Jin Ge explained, “It will not lead to competition; rather, it will foster synergistic development. Leveraging our accumulated industry experience and omics data, we can, on one hand, reach consensus with clinicians on translational research, establish strong collaborative partnerships with them, and deploy integrated diagnostic and therapeutic services directly to consumers (To C). On the other hand, we can pursue synergistic development with industry peers, helping supply chain partners accelerate integration efficiency and promoting positive, high-speed growth across the industry.”

Furthermore, in the realm of integrated diagnosis and treatment in urology, Gloriousmed has closely collaborated with leading urology experts in China, deeply engaging in research translation projects and jointly developing industry guidelines and consensus statements, thereby advancing academic development and clinical applications in the field of precision urologic medicine. Gloriousmed also actively partners with pharmaceutical companies both domestically and internationally, covering the entire drug lifecycle—from pre-market biomarker discovery to post-market monitoring and evaluation—providing comprehensive technical support and services that accelerate the research, development, and promotion of innovative drugs.

In the course of advancing integrated diagnostics and therapeutics in precision medicine, Jin Ge shared a meaningful case study. Seven years ago, an investor friend of his was unfortunately diagnosed with bladder cancer. After seeking medical consultations worldwide, the specialists who had evaluated him all recommended radical cystectomy at that time. Following genomic sequencing, Gloriousmed advised this friend to preserve his bladder and initiate treatment with PD-L1 inhibitors first, resorting to emerging targeted therapies such as antibody-drug conjugates (ADCs) if the initial response was suboptimal. The friend accepted and followed Gloriousmed’s treatment recommendations. Jin Ge shared the latest update on his friend: “Last week, his oncologist told him, ‘Your current indicators are completely normal.’”

In fact, seven years ago, it was still relatively rare for bladder cancer patients in China to opt for bladder-preserving therapy.Why Did Gloriousmed Propose This “Uncommon” Diagnostic and Treatment Recommendation for Patients in the Context of That Time? There Are Three Reasons.

First, by establishing strong ties with clinicians and pharmaceutical companies, Gloriousmed is able to promptly and comprehensively track global drug development progress, thereby providing patients with the most up-to-date and effective diagnostic and treatment recommendations. For instance, Gloriousmed has maintained close attention to targeted therapies such as antibody-drug conjugates (ADCs), which were not commonly used in clinical practice at the time.

Second, Gloriousmed has established a portfolio in the field of bladder cancer, including urinary methylation assays, urinary sWGS (shallow Whole Genome Sequencing), and ultra-deep sequencing of blood-based ctDNA, providing a robust foundation for the detection and monitoring of bladder cancer.

Third, Gloriousmed not only focuses on the diagnosis and treatment of diseases but also emphasizes full-cycle patient management. Jin Ge shared, “During our third-year follow-up, the indicators were already quite favorable.”

Furthermore, the application of big data and artificial intelligence (AI) technologies in precision medicine has brought new breakthroughs to the diagnosis and treatment of urological diseases. By integrating large volumes of clinical and omics data and leveraging AI algorithms for analysis and mining, physicians can more accurately predict disease progression and therapeutic outcomes, thereby providing more precise guidance for patient care. In this regard, Gloriousmed has established a specialized team integrating bioinformatics, IT, and AI, which not only assists clinicians in making faster and more accurate diagnoses but also provides a scientific basis for patients’ treatment plans.

Overall, the practice and application of precision medicine in urology have achieved significant results and demonstrated broad prospects for development. We look forward to leveraging technological innovation, multidisciplinary collaboration, the promotion of personalized medicine, and the deep integration of big data and artificial intelligence. Through synergistic efforts with partners across the industry chain, Gloriousmed aims to deliver more precise, efficient, and accessible medical services to patients with urological diseases.